BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22071315)

  • 1. Treatment of neurogenic diabetes insipidus.
    Chanson P; Salenave S
    Ann Endocrinol (Paris); 2011 Dec; 72(6):496-9. PubMed ID: 22071315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus.
    Kataoka Y; Nishida S; Hirakawa A; Oiso Y; Arima H
    Endocr J; 2015; 62(2):195-200. PubMed ID: 25382102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of central diabetes insipidus with oral desmopressin lyophilisate in infants.
    Korkmaz HA; Demir K; Kılıç FK; Terek D; Arslanoğlu S; Dizdarer C; Ozkan B
    J Pediatr Endocrinol Metab; 2014 Sep; 27(9-10):923-7. PubMed ID: 24854529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study.
    Arima H; Oiso Y; Juul KV; Nørgaard JP
    Endocr J; 2013; 60(9):1085-94. PubMed ID: 23811987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability in Oral Desmopressin Dose Requirements in Children with Central Diabetes Insipidus.
    Almutlaq N; Eugster EA
    J Pediatr; 2021 Dec; 239():228-230. PubMed ID: 34487771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment with sublingual desmopressin in two infants with hydranencephaly and central diabetes insipidus].
    Marín GR; Baspineiro B; Vilca I
    Arch Argent Pediatr; 2018 Feb; 116(1):e93-e97. PubMed ID: 29333830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
    Kim RJ; Malattia C; Allen M; Moshang T; Maghnie M
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():115-23. PubMed ID: 16456490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurogenic diabetes insipidus.
    Jane JA; Vance ML; Laws ER
    Pituitary; 2006; 9(4):327-9. PubMed ID: 17080264
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of subcutaneous DDAVP in infants with central diabetes insipidus.
    Blanco EJ; Lane AH; Aijaz N; Blumberg D; Wilson TA
    J Pediatr Endocrinol Metab; 2006 Jul; 19(7):919-25. PubMed ID: 16995572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of diabetes insipidus and hyponatraemia.
    Christ-Crain M; Hoorn EJ; Sherlock M; Thompson CJ; Wass JAH
    Eur J Endocrinol; 2020 Jul; 183(1):G9-G15. PubMed ID: 32380474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comments on "Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study"--efficacy and safety of orally disintegrating desmopressin tablets in patients with central diabetes insipidus.
    Kamoi K
    Endocr J; 2013; 60(9):1115. PubMed ID: 23863202
    [No Abstract]   [Full Text] [Related]  

  • 12. Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: a retrospective study of switching from intranasal desmopressin.
    Murakami T; Hatoko T; Nambu T; Matsuda Y; Matsuo K; Yonemitsu S; Muro S; Oki S
    Endocr J; 2014; 61(8):773-9. PubMed ID: 24849384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy.
    Smego AR; Backeljauw P; Gutmark-Little I
    J Clin Endocrinol Metab; 2016 May; 101(5):2084-8. PubMed ID: 27011115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Central diabetes insipidus: diagnosis and management].
    Ballan BK; Hernandez A; Rodriguez EG; Meyer P
    Rev Med Suisse; 2012 Nov; 8(362):2158, 2160-4. PubMed ID: 23240316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients.
    Juul KV; Schroeder M; Rittig S; Nørgaard JP
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2181-7. PubMed ID: 24527719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of sarcoidosis with diabetes insipidus].
    Sugiyama K; Mukae H; Sakamoto N; Iwata A; Amenomori M; Ishimoto H; Miyazaki H; Hisatomi K; Ishii H; Nakayama S; Ishimatsu Y; Kohno S
    Nihon Kokyuki Gakkai Zasshi; 2007 Jan; 45(1):105-9. PubMed ID: 17313038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term hormone replacement treatment in a horse with central diabetes insipidus.
    Durie I; van Galen G
    J Vet Intern Med; 2020 Mar; 34(2):1013-1017. PubMed ID: 31960998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central diabetes insipidus following carbon monoxide poisoning.
    Chang MY; Lin JL
    Am J Nephrol; 2001; 21(2):145-9. PubMed ID: 11359023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of central diabetes insipidus with oral desmopressin in a patient with ectrodactyly and cleft lip/palate (ECP) syndrome.
    Ozaydin E; Aycan Z; Yusufoğlu AM; Cetinkaya E; Ergen S; Unal S; Köse G
    Turk J Pediatr; 2009; 51(1):89-93. PubMed ID: 19378901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmopressin 30 years in clinical use: a safety review.
    Vande Walle J; Stockner M; Raes A; Nørgaard JP
    Curr Drug Saf; 2007 Sep; 2(3):232-8. PubMed ID: 18690973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.